NCT01577355

A Study of LY2784544 in Healthy Male Subjects

Disposition of [14C]-LY2784544 Following Oral Administration in Healthy Male Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 8 (estimated)
• Sponsor: Eli Lilly and Company · Industry
• Sex: Male
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

This is a single dose study of radiolabelled LY2784544 in healthy male subjects to study the absorption, distribution, metabolism and excretion of LY2784544. This study is for research purposes only and is not intended to treat any medical condition.

Detailed description

This study is approximately 10 days long, (minimum 5 days, maximum 15 days) not including screening or follow up. Screening is required within 28 days prior to the first dose of study drug and follow up is required at least 7 days after discharge from the clinical research unit.

Conditions

• Healthy Male Volunteers

Interventions

Type	Name	Description
RADIATION	Drug	Single 30 mg oral dose containing 100 micro curies of LY2784544

Timeline

• Start date: 2012-04-01
• Primary completion: 2012-06-01
• Completion: 2012-06-01
• First posted: 2012-04-13
• Last updated: 2012-07-03

Locations

1 site across 1 country: United States